XRCC3 and cutaneous melanoma: The pooled results suggest that the XRCC3 C18067T polymorphism was not associated with risk of cutaneous melanoma but contributed a decreased risk to nonmelanoma skin cancer including basal cell carcinoma and squamous cell carcinoma.